US Stock Insider Trading | ResMed discloses two insider transactions on February 6

K-LinePoet · 2026-03-06T04:48:33+00:00

ResMed (RMD) disclosed internal trading activities on February 6, 2026. Directors FARRELL PETER C and executive Rider Michael J, among others, sold stocks on February 4, involving significant quantities and amounts. The company was founded in 1994, focusing on medical devices and software, dedicated to improving the quality of life for patients with respiratory diseases.

K-LinePoet

2026-03-06 04:48:33

Abstract generation in progress

On February 6, 2026, ResMed (RMD) disclosed two insider transactions. Director FARRELL PETER C sold 2,000 shares on February 4, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 6, 2026	Executive	Rider Michael J	February 4, 2026	Sell	50	260.00	$13,000
February 6, 2026	Director	FARRELL PETER C	February 4, 2026	Sell	2,000	251.31	$502,620
February 3, 2026	Executive	Sandercock Brett	February 2, 2026	Sell	1,000	257.03	$257,030
January 9, 2026	Director	FARRELL PETER C	January 7, 2026	Sell	2,000	248.83	$497,660
January 8, 2026	Director	Farrell Michael J.	January 7, 2026	Sell	4,991	248.46	$1,240,100
January 8, 2026	Director	Farrell Michael J.	January 7, 2026	Buy	4,991	146.34	$730,400
January 5, 2026	Executive	Rider Michael J	January 2, 2026	Sell	50	241.75	$12,088
January 5, 2026	Executive	Sandercock Brett	January 2, 2026	Sell	1,000	241.75	$241,750
December 9, 2025	Director	Farrell Michael J.	December 8, 2025	Buy	4,991	146.34	$730,400
December 9, 2025	Director	Farrell Michael J.	December 8, 2025	Sell	4,991	251.41	$1,253,600

[Company Profile]

ResMed Inc. is a Delaware corporation founded in March 1994. The company is a global leader in the development, manufacturing, distribution, and marketing of medical equipment and cloud-based software applications that diagnose, treat, and manage respiratory diseases, including sleep apnea, chronic obstructive pulmonary disease (COPD), neuromuscular diseases, and other chronic conditions. The company’s products and solutions aim to improve patients’ quality of life, reduce the impact of chronic diseases, and lower healthcare costs as the global healthcare system continues to shift care from hospitals to homes and low-cost settings. Its cloud-based digital health software and devices are designed to provide connected care to enhance treatment outcomes and increase efficiency for providers.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes